Oragenics Presents Engineering of Improved Lantibiotic Variants at American Society for Microbiology (ASM) Conference on Antibacterial Development December 15, 2016
U.S. FDA Grants Fast Track Designation for the Development of Oragenics’ AG013 for Oral Mucositis November 21, 2016
Oragenics Receives Supportive FDA Feedback for Initiating a Phase 2 Study Protocol for Oral Mucositis Treatment August 30, 2016
Oragenics Selects New Lantibiotic for Further Development in Clostridium difficile Infections August 23, 2016
Oragenics Announces Receipt of Payment in Full under Promissory Note in Connection with Sale of Consumer Probiotic Business August 1, 2016
Oragenics Announces Entry into Definitive Agreement to Sell Consumer Probiotic Business June 23, 2016
Oragenics Announces new President, Chief Executive Officer and Member of the Board of Directors June 6, 2016
